TY  - BOOK
AU  - Pacha, Homam Moussa
AU  - Soud, Mohamad
TI  - In-Hospital Outcomes of Transcatheter Aortic Valve Implantation in Patients With Mitral Valve Stenosis
SN  - 0002-9149
PY  - 2019///
KW  - *Aortic Valve Stenosis/su [Surgery]
KW  - *Aortic Valve/su [Surgery]
KW  - *Mitral Valve Stenosis/co [Complications]
KW  - *Postoperative Complications/ep [Epidemiology]
KW  - *Risk Assessment/mt [Methods]
KW  - *Transcatheter Aortic Valve Replacement
KW  - Aged
KW  - Aged, 80 and over
KW  - Aortic Valve Stenosis/co [Complications]
KW  - Cardiac Catheterization/mt [Methods]
KW  - Female
KW  - Follow-Up Studies
KW  - Hospital Mortality/td [Trends]
KW  - Humans
KW  - Incidence
KW  - Male
KW  - Prognosis
KW  - Retrospective Studies
KW  - Risk Factors
KW  - Survival Rate/td [Trends]
KW  - Time Factors
KW  - United States/ep [Epidemiology]
KW  - MedStar Washington Hospital Center
KW  - Medicine/Internal Medicine
KW  - Journal Article
N1  - Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006
N2  - Copyright (c) 2019 Elsevier Inc. All rights reserved; Little is known about the outcome of patients with mitral stenosis (MS) who underwent transcatheter aortic valve implantation (TAVI). Therefore, we sought to evaluate the potential impact of MS on the outcome of patients who underwent TAVI using the US national cohort. Using weighted data from the National Inpatient Sample database between 2011 and 2015, we identified patients who had undergone a TAVI as a primary procedure. Patients with MS diagnosis were compared with those without MS. Univariate and multivariate logistic regression analyses were performed for the outcomes of in-hospital mortality and postprocedural complications. Outcomes were also stratified by the type to TAVI (endovascular vs transapical). A total of 62,110 patients underwent TAVI (mean age 81 +/- 8.72, 47.4% females, and 3.7% African-Americans) and 887 patients had MS (1.43%). Patients with concomitant MS had higher in-hospital mortality (5.1% vs 3.5% adjusted odds ratio [aOR] 1.455; 95% confidence interval [CI] 1.059 to 2.001, p=0.021), major adverse cardiac events (9.0% vs 7.1% aOR 1.297; 95% CI 1.012 to 1.663, p=0.040), major bleeding (16.3% vs 12.1% aOR 1.303; 95% CI 1.067 to 1.593, p=0.010), cardiac complications (21.8% vs 16.0% aOR 1.536; 95% CI, 1.300 to 1.815, p < 0.001), and acute myocardial infarction (4.5% vs 2.8% aOR 1.783; 95% CI 1.249 to 2.545, p=0.007) when compared with patients without MS. In conclusion, MS is an independent risk factor for mortality and morbidity after TAVI procedure for patients with severe aortic stenosis
UR  - https://dx.doi.org/10.1016/j.amjcard.2019.02.005
ER  -